Business Wire

IQM

9.12.2021 17:02:06 CET | Business Wire | Press release

Share
IQM: A New Super-cooled Microwave Source Boosts the Scale-up of Quantum Computers

In a new work published in Nature Electronics, researchers in Finland have developed a circuit that produces the high-quality microwave signals required to control quantum computers while operating at temperatures near absolute zero. This is a key step towards moving the control system closer to the quantum processor, which may make it possible to greatly increase the number of qubits in the processor.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209005593/en/

One of the factors limiting the size of quantum computers is the mechanism used to control the qubits in quantum processors. This is normally accomplished using a series of microwave pulses, and because quantum processors operate at temperatures near absolute zero, the control pulses are normally brought into the cooled environment via broadband cables from room temperature.

As the number of qubits grows, so does the number of cables needed. This limits the potential size of a quantum processor, because the refrigerators cooling the qubits would have to become larger to accommodate more and more cables while also working harder to cool them down – ultimately a losing proposition.

A research consortium including Aalto University , VTT Technical Research Centre of Finland , and IQM Quantum Computers has now developed a key component of the solution to this conundrum. ‘We have built a precise microwave source that works at the same extremely low temperature as the quantum processors, approximately -273 degrees,’ says the team leader Mikko Möttönen , Professor at Aalto University and VTT Technical Research Centre of Finland and a Co-Founder and Chief Scientist of IQM.

The new microwave source is an on-chip device that can be integrated with a quantum processor. Less than a millimetre in size, it potentially removes the need for high-frequency control cables connecting different temperatures. With this low-power, low-temperature microwave source, it may be possible to use smaller cryostats while still increasing the number of qubits in a processor.

‘Our device produces one hundred times more power than previous versions, which is enough to control qubits and carry out quantum logic operations,’ says Möttönen. ‘It produces a very precise sine wave, oscillating over a billion times per second. As a result, errors in qubits from the microwave source are very infrequent, which is important when implementing precise quantum logic operations.’

However, a continuous-wave microwave source, such as the one produced by this device, cannot be used as is to control qubits. First, the microwaves must be shaped into pulses. The team is currently developing methods to quickly switch the microwave source on and off.

Even without a switching solution to create pulses, an efficient, low-noise, low-temperature microwave source could be useful in a range of quantum technologies, such as quantum sensors.

‘In addition to quantum computers and sensors, the microwave source can act as a clock for other electronic devices. It can keep different devices in the same rhythm, allowing them to induce operations for several different qubits at the desired instant of time,’ explains Möttönen.

The theoretical analysis and the initial design were carried out by Juha Hassel and others at VTT. Hassel, who started this work at VTT, is currently the head of engineering and development at IQM Quantum Computers, Pan-European leader in quantum computers. The device was then built at VTT and operated by postdoctoral research Chengyu Yan and his colleagues at Aalto University using the OtaNano research infrastructure. Yan is currently an associate professor at Huazhong University of Science and Technology, China. The teams involved in this research are part of the Academy of Finland Centre of Excellence in Quantum Technology (QTF) and the Finnish Quantum Institute (InstituteQ).

Original research paper

Chengyu Yan, Juha Hassel, Visa Vesterinen, Jinli Zhang, Joni Ikonen, Leif Grönberg, Jan Goetz and Mikko Möttönen, A low-noise on-chip coherent microwave source , Nature Electronics, DOI:10.1038/s41928-021-00680-z (2021)

https://doi.org/10.1038/s41928-021-00680-z (link opens after embargo ceases)

Preprint available at any time: https://arxiv.org/pdf/2103.07617

More pictures in the material bank : https://materialbank.aalto.fi/l/sjcg87sHxFfR

About IQM Quantum Computers

IQM is a Pan-European leader in quantum computers.

IQM provides on-site quantum computing for research labs and supercomputing data centers and offers full access to its hardware. For industrial customers, IQM delivers quantum advantage through a unique application-specific co-design approach.

IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium (Q-Exa) is building Germany’s quantum computer that will be integrated into an HPC supercomputer to create an accelerator for future scientific research. IQM has offices in Bilbao, Munich and Espoo and employs over 130 people. More information: www.meetiqm.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye